Proteolix, Inc. to Present Preclinical Data on Carfilzomib and PR-957 at the 2009 ACR/ARHP Annual Meeting
10/19/2009 9:10:17 AM
More...
|
Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
6/15/2009 9:38:57 AM
More...
|
Proteolix, Inc. Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
6/8/2009 10:45:01 AM
More...
|
Proteolix, Inc. Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 American Society of Clinical Oncology Annual Meeting
6/2/2009 10:43:14 AM
More...
|
Proteolix, Inc. Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 American Society of Clinical Oncology Annual Meeting
6/1/2009 11:12:25 AM
More...
|
Proteolix, Inc. to Present Carfilzomib Clinical Data During the 2009 American Society of Clinical Oncology Annual Meeting
5/15/2009 10:15:09 AM
More...
|
Proteolix, Inc. Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
4/16/2009 11:48:53 AM
More...
|
Proteolix, Inc. Announces the Appointment of John Scarlett, M.D., President and CEO
2/25/2009 7:30:44 AM
More...
|
Proteolix, Inc. Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma
12/9/2008 8:23:37 AM
More...
|
Proteolix, Inc. Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
12/8/2008 12:46:27 PM
More...
|
|